Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival

Cancer

Volumn 103, Issue 9, 2005, Pages 1770-1777

  Wiseman, Sam M ^a,b,c   Makretsov, Nikita ^a,b   Nielsen, Torsten O ^a,b   Gilks, Blake ^a,b   Yorida, Erika ^a,b   Cheang, Maggie ^a,b   Turbin, Dmitry ^a,b   Gelmon, Karen ^a,b   Huntsman, David G ^a,b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

Author keywords

Breast carcinoma; HER 1; HER 2; HER 3; HER 4; Prognosis; Tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CARCINOMA; CANCER MORTALITY; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY;

BREAST NEOPLASMS; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 17644387160     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20970     Document Type: Article

References (40)

1. Bundred NJ. Prognostic and predictive factors in breast cancer. Cancer Treat Rev. 2001;27:137-142.
2. Mouridsen H, Rose C, Brodie A, et al. Challenges in the endocrine management of breast cancer. Breast. 2003;12(S2):12-19.
3. Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001;12(S1):3-8.
4. Citri A, Skaria B, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res. 2003;284:54-65.
5. Stern DF. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res. 2000;2:176-183.
6. Olayioye M. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res. 2001;3:385-389.
7. Miller KD. The role of ErbB inhibitors in trastuzumab resistance. Oncologist. 2004;9(S3):16-19.
8. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 1996;16:5276-5287.
9. Pinkas-Kramarski R, Shelly M, Guarino BC, et al. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol. 1998;18:6090-6101.
10. Siegel P, Ryan E, Cardiff R, et al. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J. 1999;18:2149-2164.
11. Alimandi M, Romano A, Curia M, et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene. 1995:10:1813-1821.
12. Hudelist G, Singer CF, Manavi M, et al. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res. 2003;80:353-361.
13. Muss H, Thor A, Berry D, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260-1266.
14. Carlomagno C, Perrone F, Fallo C, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996;14:2702-2708.
15. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001;19:2722-2730.
16. Pegram MD, Lopez A, Konecny G, et al. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol. 2000;27(6 Suppl 11):21-25.
17. Artega CL, Moulder S, Yakes F. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol. 2002;29(3 Suppl 11):4-10.
18. Parker RL, Huntsman DG, Lesack DW, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 2002;117:723-728.
19. Reiner A, Neumeister B, Spona J, et al. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res. 1990;50:7057-7061.
20. Liu CL, Prapong W, Natkunam Y, et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol. 2002;161:1557-1565.
21. Slamon DL, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
22. Eissa S, Khalifa A, el-Gharib A, et al. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer. Anticancer Res. 1997;17:3091-3097.
23. Sjogren S, Inganas M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998;16:462-469.
24. Lewis S, Locker A, Todd JH, et al. Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol. 1990;43:385-389.
25. Sainsbury JR, Farndon JR, Needham GK, et al. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987;1:1398-1402.
26. Witton C, Reeves J, Going J, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003;200:290-297.
27. Esteva F, Hortobagyi G, Sahin A, et al. Expression of erb/ HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res. 2001;7:171-177.
28. Lodge A, Anderson J, Gullick W, et al. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. J Clin Pathol. 2003;56:300-304.
29. Kew TY, Bell JA, Finder SE, et al. c-erbB-4 protein expression in human breast cancer. Br J Cancer. 2000;82:1163-1170.
30. Tovey SM, Witton CJ, Bartlett JM, et al. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res. 2004;6:246-251.
31. Suo Z, Risberg B, Kalsson M, et al. EGFR family expression in breast carcinomas. C-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol. 2001;196:17-25.
32. Suo Z, Yang H, Mei Q, et al. Type 1 protein tyrosine kinases in Chinese breast carcinomas: a clinicopathologic study. Int J Surg Pathol. 2001;9:177-187.
33. Deal IT, Dolled-Filhart M, D'Aquila T, et al. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer. 2003;97:1841-1848.
34. Slamon DJ. The future of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors. Oncologist. 2004;9(S3):1-3.
35. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.
36. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
37. Moulder SL, Yakes FM, Muthuswamy SK, et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 2001;61:8887-8895.
38. Rusnak DW, Affleck K, Cockerill SG, et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001;61:7196-7203.
39. Burris HA. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist. 2004;9(S3):10-15.
40. Allen LF, Eiseman IA, Fry DW, et al. CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin Oncol. 2003;30(S16):65-78.